Literature DB >> 4030111

Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea.

B Aronsson, M Granström, R Möllby, C E Nord.   

Abstract

Consecutive serum samples from 61 patients with Clostridium difficile diarrhoea were investigated for antibody response to C. difficile toxins A and B in an indirect enzyme immunoassay (ELISA) and in a neutralization assay against C. difficile cytotoxin. Sera from 64 blood donors, elderly healthy females and patients with other known intestinal enteropathogens served as controls. An immune response was detected by ELISA in approximately half of the patients with C. difficile diarrhoea. The specificity of the ELISA was 94% or 97%, depending on the control material used. Furthermore, a correlation was found between clinical recovery without relapse of C. difficile diarrhoea and high IgG titers to toxin B in the ELISA, and/or appearance of neutralizing antibodies. It is concluded that the ELISA for detection of serum antibodies to C. difficile toxins may be of diagnostic value in combination with the conventional tissue culture assay for cytotoxin in stool. High ELISA IgG titres to toxin B and/or the appearance of neutralizing antibodies may also be a positive prognostic sign in patients with C. difficile diarrhoea.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4030111     DOI: 10.1007/bf01642866

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  12 in total

1.  Antibodies to Clostridium difficile cytotoxin in a pediatric population.

Authors:  R H George; S Hartley
Journal:  Am J Dis Child       Date:  1983-10

2.  Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies.

Authors:  J M Libby; T D Wilkins
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

3.  Antibody response to Shigella sonnei infection determined by an enzyme-linked immunosorbent assay.

Authors:  E Ekwall; S Haeggmann; M Kalin; B Svenungsson; A A Lindberg
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

4.  Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett; F J Tedesco; S Shull; B Lowe; T Chang
Journal:  Gastroenterology       Date:  1980-03       Impact factor: 22.682

5.  Identification of Clostridium difficile as a cause of pseudomembranous colitis.

Authors:  R H George; J M Symonds; F Dimock; J D Brown; Y Arabi; N Shinagawa; M R Keighley; J Alexander-Williams; D W Burdon
Journal:  Br Med J       Date:  1978-03-18

6.  Enzyme-linked immunosorbent assay (ELISA) for antibodies to Clostridium difficile toxins in patients with pseudomembranous colitis and antibiotic-associated diarrhoea.

Authors:  B Aronsson; M Granström; R Möllby; C E Nord
Journal:  J Immunol Methods       Date:  1983-06-10       Impact factor: 2.303

7.  Serum antibody response to toxins A and B of Clostridium difficile.

Authors:  R Viscidi; B E Laughon; R Yolken; P Bo-Linn; T Moench; R W Ryder; J G Bartlett
Journal:  J Infect Dis       Date:  1983-07       Impact factor: 5.226

8.  Clostridium difficile and antibiotic associated diarrhoea in Sweden.

Authors:  B Aronsson; R Möllby; C E Nord
Journal:  Scand J Infect Dis Suppl       Date:  1982

9.  Occurrence of toxin-producing Clostridium difficile in antibiotic-associated diarrhea in Sweden.

Authors:  B Aronsson; R Möllby; C E Nord
Journal:  Med Microbiol Immunol       Date:  1981       Impact factor: 3.402

10.  Clostridium difficile and cytotoxin in feces of patients with antimicrobial agent-associated pseudomembranous colitis.

Authors:  W L George; R D Rolfe; G K Harding; R Klein; C W Putnam; S M Finegold
Journal:  Infection       Date:  1982       Impact factor: 3.553

View more
  30 in total

1.  Serum antibody responses to Clostridium difficile toxin A: predictive and protective?

Authors:  C Phillips
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

Review 2.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

3.  Clostridium difficile colitis in children with cystic fibrosis.

Authors:  Sunny Zaheed Hussain; Cathy Chu; David P Greenberg; David Orenstein; Seema Khan
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

Review 4.  Acute and chronic pouchitis--pathogenesis, diagnosis and treatment.

Authors:  Bo Shen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-04-17       Impact factor: 46.802

Review 5.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Clostridioides difficile Infection Induces an Inferior IgG Response to That Induced by Immunization and Is Associated with a Lack of T Follicular Helper Cell and Memory B Cell Expansion.

Authors:  Souwelimatou Amadou Amani; Tyler Shadid; Jimmy D Ballard; Mark L Lang
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

7.  Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine.

Authors:  M Warny; A Fatimi; E F Bostwick; D C Laine; F Lebel; J T LaMont; C Pothoulakis; C P Kelly
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

Review 8.  Clostridium difficile infection among hematopoietic stem cell transplant recipients: beyond colitis.

Authors:  Carolyn D Alonso; Kieren A Marr
Journal:  Curr Opin Infect Dis       Date:  2013-08       Impact factor: 4.915

Review 9.  Antibodies for treatment of Clostridium difficile infection.

Authors:  David P Humphreys; Mark H Wilcox
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

10.  Colonic IgA producing cells and macrophages are reduced in recurrent and non-recurrent Clostridium difficile associated diarrhoea.

Authors:  S S Johal; C P Lambert; J Hammond; P D James; S P Borriello; Y R Mahida
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.